Search company, investor...
Chiasso company logo

Chiasso

chiasso.com

Founded Year

1985

Stage

Acquired | Acquired

Total Raised

$3M

Valuation

$0000 

Revenue

$0000 

About Chiasso

Chiasso is refreshing contemporary furniture and modern home accessories... that make the ordinary, well, extraordinary. from the perfect piece of contemporary furniture to the fun, home decor gift, we are your source for exceptional modern style and quality. Rest assured, we strive for customer service that is as equally outstanding as our product.

Headquarters Location

1440 North Dayton Street Suite 307

Chicago, Illinois, 60622,

United States

312-932-2000

Missing: Chiasso's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Chiasso's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Chiasso News

Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region

Nov 28, 2022

commercialize AKYNZEO® in the Baltic region CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, and Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, announce today the signing of an exclusive marketing and distribution agreement in the Baltic region for AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults. Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented: “This agreement once again demonstrates the Farma Mondo’s mission to provide access to medicines where no one else can. We are proud to partner with Helsinn in the Baltic region as we continue to expand our infrastructure worldwide to further support patients’ unmet needs.” Giorgio Calderari, Helsinn Group CEO, commented: “It is a pleasure to welcome Farma Mondo to our expanding network of partners for AKYNZEO® and we are thankful to be able to utilize their reach in the Baltic region to enable patient access to this much needed treatment. We look forward to working with them in order to enhance quality of life for patients undergoing chemotherapy in these countries.” About AKYNZEO® AKYNZEO® is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. A single dose of AKYNZEO® given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days. About Farma Mondo Group Farma Mondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization. For more information about Farma Mondo please visit: www.farmamondo.com About Helsinn Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases. Helsinn is a third-generation family-owned company, that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. Helsinn’s unique business model enables it to in-license or acquire assets at a late stage of development. It has a commercial presence in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its network of long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd. Helsinn plays an active and central role in promoting social transformation in favor of people and the environment. Sustainability is at the heart of everything we do, which is reinforced in the company’s strategic plan by a commitment to sustainable growth. To learn more about Helsinn please visit:  www.helsinn.com For more information:

Chiasso Frequently Asked Questions (FAQ)

  • When was Chiasso founded?

    Chiasso was founded in 1985.

  • Where is Chiasso's headquarters?

    Chiasso's headquarters is located at 1440 North Dayton Street, Chicago.

  • What is Chiasso's latest funding round?

    Chiasso's latest funding round is Acquired.

  • How much did Chiasso raise?

    Chiasso raised a total of $3M.

  • Who are the investors of Chiasso?

    Investors of Chiasso include CS Capital Partners and Holden Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.